New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:45 EDTINSYInsys Therapeutics price target raised to $99 from $50 at JMP Securities
JMP Securities increased its price target on Insys after the company reported higher than expected earnings. The firm expects the company to benefit from continued growth in its Subsys drug and further advances in its pipeline. JMP Securities reiterates an Outperform rating on the stock.
News For INSY From The Last 14 Days
Check below for free stories on INSY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
09:11 EDTINSYOn The Fly: Pre-market Movers
Subscribe for More Information
07:07 EDTINSYInsys Therapeutics receives FDA orphan drug designation for CBD
Insys Therapeutics announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol, or CBD, for the treatment of glioblastoma multiforme, or GBM, the most common and most aggressive malignant primary brain tumor in humans. In addition to receiving orphan drug designation, Insys has recently entered into an exclusive licensing agreement with California Pacific Medical Center on behalf of its Research Institute, or CPMCRI, based in San Francisco to license CPMCRI's patent rights related to the usage of cannabinoids for the treatment of GBM.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use